DE60117859T2 - HARNSTOFFSUBSTITUIERTE IMIDAZOCHINOLINETHER und Arzneimittel, die diese umfassen. - Google Patents

HARNSTOFFSUBSTITUIERTE IMIDAZOCHINOLINETHER und Arzneimittel, die diese umfassen. Download PDF

Info

Publication number
DE60117859T2
DE60117859T2 DE60117859T DE60117859T DE60117859T2 DE 60117859 T2 DE60117859 T2 DE 60117859T2 DE 60117859 T DE60117859 T DE 60117859T DE 60117859 T DE60117859 T DE 60117859T DE 60117859 T2 DE60117859 T2 DE 60117859T2
Authority
DE
Germany
Prior art keywords
alkyl
alkylene
aryl
heteroaryl
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60117859T
Other languages
German (de)
English (en)
Other versions
DE60117859D1 (de
Inventor
L. Stephen Mahtomedi CROOKS
W. George Eagan GRIESGRABER
D. Philip Woodbury HEPPNER
A. Bryon River Falls MERRILL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3M Innovative Properties Co
Original Assignee
3M Innovative Properties Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3M Innovative Properties Co filed Critical 3M Innovative Properties Co
Application granted granted Critical
Publication of DE60117859D1 publication Critical patent/DE60117859D1/de
Publication of DE60117859T2 publication Critical patent/DE60117859T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/08Antibacterial agents for leprosy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
DE60117859T 2000-12-08 2001-12-06 HARNSTOFFSUBSTITUIERTE IMIDAZOCHINOLINETHER und Arzneimittel, die diese umfassen. Expired - Fee Related DE60117859T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25421800P 2000-12-08 2000-12-08
US254218P 2000-12-08
PCT/US2001/046696 WO2002046191A2 (en) 2000-12-08 2001-12-06 Urea substituted imidazoquinoline ethers

Publications (2)

Publication Number Publication Date
DE60117859D1 DE60117859D1 (de) 2006-05-04
DE60117859T2 true DE60117859T2 (de) 2006-11-23

Family

ID=22963391

Family Applications (3)

Application Number Title Priority Date Filing Date
DE60117859T Expired - Fee Related DE60117859T2 (de) 2000-12-08 2001-12-06 HARNSTOFFSUBSTITUIERTE IMIDAZOCHINOLINETHER und Arzneimittel, die diese umfassen.
DE60111076T Expired - Lifetime DE60111076T2 (de) 2000-12-08 2001-12-06 Thioethersubstituierte imidazochinoline
DE60126645T Expired - Fee Related DE60126645T2 (de) 2000-12-08 2001-12-06 Sulfonamidether - substituierte imidazochinoline

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE60111076T Expired - Lifetime DE60111076T2 (de) 2000-12-08 2001-12-06 Thioethersubstituierte imidazochinoline
DE60126645T Expired - Fee Related DE60126645T2 (de) 2000-12-08 2001-12-06 Sulfonamidether - substituierte imidazochinoline

Country Status (31)

Country Link
US (8) US6656938B2 (enExample)
EP (6) EP1341791B1 (enExample)
JP (7) JP2004529078A (enExample)
KR (6) KR20030070050A (enExample)
CN (6) CN1252070C (enExample)
AR (6) AR035669A1 (enExample)
AT (3) ATE353895T1 (enExample)
AU (12) AU3249702A (enExample)
BR (6) BR0116047A (enExample)
CA (6) CA2436984A1 (enExample)
CY (2) CY1105586T1 (enExample)
CZ (6) CZ20031562A3 (enExample)
DE (3) DE60117859T2 (enExample)
DK (3) DK1343784T3 (enExample)
EE (6) EE200300275A (enExample)
ES (3) ES2260323T3 (enExample)
HR (6) HRP20030462A2 (enExample)
HU (6) HUP0700062A2 (enExample)
IL (6) IL155903A0 (enExample)
MX (6) MXPA03004973A (enExample)
NO (6) NO20032449L (enExample)
NZ (6) NZ526086A (enExample)
PL (7) PL365995A1 (enExample)
PT (2) PT1341791E (enExample)
RU (6) RU2308456C2 (enExample)
SI (1) SI1341790T1 (enExample)
SK (6) SK6842003A3 (enExample)
TW (3) TWI222972B (enExample)
UA (2) UA74852C2 (enExample)
WO (6) WO2002046193A2 (enExample)
ZA (6) ZA200305275B (enExample)

Families Citing this family (209)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
UA67760C2 (uk) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6331539B1 (en) * 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6573273B1 (en) 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6916925B1 (en) 1999-11-05 2005-07-12 3M Innovative Properties Co. Dye labeled imidazoquinoline compounds
JP3436512B2 (ja) * 1999-12-28 2003-08-11 株式会社デンソー アクセル装置
US6677347B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6667312B2 (en) * 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6545016B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6664264B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
UA74852C2 (en) * 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6660735B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6660747B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US7226928B2 (en) * 2001-06-15 2007-06-05 3M Innovative Properties Company Methods for the treatment of periodontal disease
US20030199538A1 (en) * 2001-11-29 2003-10-23 3M Innovative Properties Company Pharmaceutical formulation comprising an immune response modifier
CA2365732A1 (en) 2001-12-20 2003-06-20 Ibm Canada Limited-Ibm Canada Limitee Testing measurements
US6677349B1 (en) * 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
IL147953A (en) 2002-02-01 2008-04-13 Meir Bialer Derivatives and pharmaceutical compositions of n-hydroxymethyl tetramethylcyclopropyl-
HUE025145T2 (en) 2002-02-22 2016-01-28 Meda Ab A method for reducing and treating immunosuppression induced by ultraviolet B radiation
GB0211649D0 (en) * 2002-05-21 2002-07-03 Novartis Ag Organic compounds
EP1513524A4 (en) 2002-06-07 2008-09-03 3M Innovative Properties Co WITH ETHER SUBSTITUTED IMIDAZOPYRIDINE
JP4903997B2 (ja) * 2002-07-02 2012-03-28 サザン リサーチ インスティチュート FtsZの阻害剤およびそれらの用途
DK1545597T3 (da) * 2002-08-15 2011-01-31 3M Innovative Properties Co Immunstimulerende sammensætninger og fremgangsmåde til stimulering af en immunrespons
EP1542688A4 (en) 2002-09-26 2010-06-02 3M Innovative Properties Co 1H-imidazo dimers
WO2004058759A1 (en) * 2002-12-20 2004-07-15 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
AU2003300184B8 (en) 2002-12-30 2009-12-03 3M Innovative Properties Company Immunostimulatory combinations
WO2004071459A2 (en) * 2003-02-13 2004-08-26 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor 8
EP1599726A4 (en) 2003-02-27 2009-07-22 3M Innovative Properties Co SELECTIVE MODULATION OF TLR-MEDIATED BIOLOGICAL ACTIVITY
AU2004218349A1 (en) * 2003-03-04 2004-09-16 3M Innovative Properties Company Prophylactic treatment of UV-induced epidermal neoplasia
US7163947B2 (en) * 2003-03-07 2007-01-16 3M Innovative Properties Company 1-Amino 1H-imidazoquinolines
TW200505458A (en) * 2003-03-07 2005-02-16 3M Innovative Properties Co 1-amino 1h-imidazoquinolines
US8426457B2 (en) 2003-03-13 2013-04-23 Medicis Pharmaceutical Corporation Methods of improving skin quality
AU2004220465A1 (en) 2003-03-13 2004-09-23 3M Innovative Properties Company Method of tattoo removal
US7699057B2 (en) * 2003-03-13 2010-04-20 3M Innovative Properties Company Methods for treating skin lesions
US20040192585A1 (en) * 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
JP2006522823A (ja) 2003-04-10 2006-10-05 スリーエム イノベイティブ プロパティズ カンパニー 免疫反応調節物質化合物の送達
EP1617845A4 (en) * 2003-04-28 2006-09-20 3M Innovative Properties Co COMPOSITIONS AND METHODS FOR INDUCING OPOID RECEPTORS
AR044466A1 (es) * 2003-06-06 2005-09-14 3M Innovative Properties Co Proceso para la preparacion de imidazo [4,5-c] piridin-4-aminas
WO2004110991A2 (en) * 2003-06-06 2004-12-23 3M Innovative Properties Company PROCESS FOR IMIDAZO[4,5-c]PYRIDIN-4-AMINES
US20050070460A1 (en) * 2003-08-05 2005-03-31 3M Innovative Properties Company Infection prophylaxis using immune response modifier compounds
US8673932B2 (en) 2003-08-12 2014-03-18 3M Innovative Properties Company Oxime substituted imidazo-containing compounds
JP4913593B2 (ja) * 2003-08-14 2012-04-11 スリーエム イノベイティブ プロパティズ カンパニー 脂質修飾された免疫応答調整剤
PL1653959T3 (pl) 2003-08-14 2015-10-30 3M Innovative Properties Co Modyfikatory odpowiedzi immunologicznej modyfikowane lipidami
EP1660122A4 (en) * 2003-08-25 2007-10-24 3M Innovative Properties Co IMMUNOSTIMULATORY COMBINATIONS AND TREATMENTS
AU2004268616B2 (en) 2003-08-25 2010-10-07 3M Innovative Properties Company Delivery of immune response modifier compounds
AR045529A1 (es) * 2003-08-27 2005-11-02 3M Innovative Properties Co Imidazoquinolinas sustituidas con grupos ariloxi o arilalquilenoxi
JP2007504172A (ja) * 2003-09-02 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー 粘膜に関連した症状の処置に関する方法
AU2004270201A1 (en) * 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for CD5+ B cell lymphoma
US20050059072A1 (en) * 2003-09-17 2005-03-17 3M Innovative Properties Company Selective modulation of TLR gene expression
NZ546274A (en) 2003-10-03 2009-12-24 3M Innovative Properties Co Pyrazolopyridines and analags thereof
US20090075980A1 (en) * 2003-10-03 2009-03-19 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and Analogs Thereof
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
US8871782B2 (en) 2003-10-03 2014-10-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
AU2004285575A1 (en) * 2003-10-31 2005-05-12 3M Innovative Properties Company Neutrophil activation by immune response modifier compounds
US8598192B2 (en) 2003-11-14 2013-12-03 3M Innovative Properties Company Hydroxylamine substituted imidazoquinolines
CA2545774A1 (en) * 2003-11-14 2005-06-02 3M Innovative Properties Company Oxime substituted imidazo ring compounds
AR046845A1 (es) * 2003-11-21 2005-12-28 Novartis Ag Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas
BRPI0416801A (pt) * 2003-11-21 2007-01-09 Novartis Ag derivados de 1h-imidazoquinolina como inibidores de proteìna sinase
WO2005051324A2 (en) * 2003-11-25 2005-06-09 3M Innovative Properties Company Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
RU2409576C2 (ru) 2003-11-25 2011-01-20 3М Инновейтив Пропертиз Компани Системы, содержащие имидазольное кольцо с заместителями, и способы их получения
EP1689361A4 (en) 2003-12-02 2009-06-17 3M Innovative Properties Co THERAPEUTIC COMBINATIONS AND PROCESSES WITH IRM COMPOUNDS
EP1694674A4 (en) * 2003-12-04 2010-07-07 3M Innovative Properties Co IMIDAZO CYCLIC ETHERS SUBSTITUTED WITH SULFONE
US8802853B2 (en) * 2003-12-29 2014-08-12 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
EP1699792A1 (en) * 2003-12-29 2006-09-13 3M Innovative Properties Company Piperazine, 1,4¨diazepane, 1,4¨diazocane, and 1,5¨diazocane fused imidazo ring compounds
US20050239735A1 (en) * 2003-12-30 2005-10-27 3M Innovative Properties Company Enhancement of immune responses
WO2005065678A1 (en) * 2003-12-30 2005-07-21 3M Innovative Properties Company Immunomodulatory combinations
JP2007517044A (ja) 2003-12-30 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー イミダゾキノリニル、イミダゾピリジニル、およびイミダゾナフチリジニルスルホンアミド
CA2559607C (en) 2004-03-15 2013-02-19 3M Innovative Properties Company Immune response modifier formulations and methods
EP1730143A2 (en) * 2004-03-24 2006-12-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
EP1735010A4 (en) * 2004-04-09 2008-08-27 3M Innovative Properties Co METHODS, COMPOSITIONS AND PREPARATIONS FOR ADMINISTRATION OF IMMUNE RESPONSE MODIFIERS (MRI)
US20050267145A1 (en) * 2004-05-28 2005-12-01 Merrill Bryon A Treatment for lung cancer
WO2005123079A2 (en) * 2004-06-14 2005-12-29 3M Innovative Properties Company Urea substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US8017779B2 (en) 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US20070259881A1 (en) * 2004-06-18 2007-11-08 Dellaria Joseph F Jr Substituted Imidazo Ring Systems and Methods
US7897609B2 (en) 2004-06-18 2011-03-01 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
WO2006065280A2 (en) 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
EP1765348B1 (en) * 2004-06-18 2016-08-03 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US20090270443A1 (en) * 2004-09-02 2009-10-29 Doris Stoermer 1-amino imidazo-containing compounds and methods
WO2006029115A2 (en) 2004-09-02 2006-03-16 3M Innovative Properties Company 2-amino 1h imidazo ring systems and methods
ES2384390T3 (es) * 2004-09-02 2012-07-04 3M Innovative Properties Company Sistemas cíclicos 1-alcoxi-1H-imidazo y métodos asociados
WO2006029223A2 (en) * 2004-09-08 2006-03-16 Children's Medical Center Corporation Method for stimulating the immune response of newborns
AU2005284835A1 (en) * 2004-09-14 2006-03-23 Novartis Vaccines And Diagnostics Inc. Imidazoquinoline compounds
JP2008515928A (ja) * 2004-10-08 2008-05-15 スリーエム イノベイティブ プロパティズ カンパニー Dnaワクチンのためのアジュバント
WO2006063072A2 (en) * 2004-12-08 2006-06-15 3M Innovative Properties Company Immunomodulatory compositions, combinations and methods
US8080560B2 (en) * 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
US8436176B2 (en) * 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
US8034938B2 (en) 2004-12-30 2011-10-11 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
JP2008526751A (ja) * 2004-12-30 2008-07-24 武田薬品工業株式会社 1−(2−メチルプロピル)−1h−イミダゾ[4,5−c][1,5]ナフチリジン−4−アミンエタンスルホナート及び1−(2−メチルプロピル)−1h−イミダゾ[4,5−c][1,5]ナフチリジン−4−アミンメタンスルホナート
JP2008526765A (ja) 2004-12-30 2008-07-24 スリーエム イノベイティブ プロパティズ カンパニー 皮膚転移の処置
EP1831226B1 (en) 2004-12-30 2012-08-08 3M Innovative Properties Company Chiral tetracyclic compounds inducing interferon biosynthesis
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
AU2006212765B2 (en) 2005-02-09 2012-02-02 3M Innovative Properties Company Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
JP2008530252A (ja) 2005-02-09 2008-08-07 コーリー ファーマシューティカル グループ,インコーポレイテッド オキシムおよびヒドロキシルアミンで置換されたチアゾロ[4,5−c]環化合物ならびに方法
CA2597446A1 (en) 2005-02-11 2006-08-31 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines and imidazonaphthyridines
JP2008530113A (ja) 2005-02-11 2008-08-07 コーリー ファーマシューティカル グループ,インコーポレイテッド オキシムおよびヒドロキシラミン置換イミダゾ[4,5−c]環化合物および方法
AU2006216844B2 (en) 2005-02-18 2012-11-08 Novartis Vaccines And Diagnostics S.R.L. Immunogens from uropathogenic escherichia coli
EP1858920B1 (en) 2005-02-18 2016-02-03 GlaxoSmithKline Biologicals SA Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
EP1851224A2 (en) * 2005-02-23 2007-11-07 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinolines
JP2008531567A (ja) * 2005-02-23 2008-08-14 コーリー ファーマシューティカル グループ,インコーポレイテッド ヒドロキシアルキル置換イミダゾキノリン化合物および方法
CA2598639A1 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazonaphthyridines
JP2008538203A (ja) * 2005-02-23 2008-10-16 コーリー ファーマシューティカル グループ,インコーポレイテッド インターフェロンの生合成を優先的に誘導する方法
CA2602098A1 (en) 2005-03-14 2006-09-21 Graceway Pharmaceuticals, Llc Method of treating actinic keratosis
EP1869043A2 (en) 2005-04-01 2007-12-26 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
WO2006107851A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
EP1874345B1 (en) * 2005-04-25 2012-08-15 3M Innovative Properties Company Immunostimulatory compositions
EP1909564A4 (en) 2005-07-18 2010-06-30 Novartis Ag SMALL ANIMAL MODEL FOR HCV REPLICATION
JP2009507856A (ja) 2005-09-09 2009-02-26 コーリー ファーマシューティカル グループ,インコーポレイテッド N−{2−[4−アミノ−2−(エトキシメチル)−1H−イミダゾ[4,5−c]キノリン−1−イル]−1,1−ジメチルエチル}メタンスルホンアミドのアミドおよびカルバマート誘導体ならびに方法
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
US8889154B2 (en) 2005-09-15 2014-11-18 Medicis Pharmaceutical Corporation Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation
US8697087B2 (en) 2005-11-04 2014-04-15 Novartis Ag Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
HUE051122T2 (hu) 2005-11-04 2021-03-01 Seqirus Uk Ltd Sejttenyészetben növesztett influenzavírusból elõállított nemvirion anti-géneket tartalmazó adjuvált vakcinák
JP2009514850A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル アジュバントとして減少した量の水中油型エマルションを有するインフルエンザワクチン
AU2006311871B2 (en) * 2005-11-04 2011-03-03 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods
NZ592713A (en) 2005-11-04 2012-12-21 Novartis Vaccines & Diagnostic Adjuvanted influenza vaccines including a cytokine-inducing agents other than an agonist of Toll-Like Receptor 9
PL1976559T6 (pl) 2006-01-27 2020-08-10 Novartis Influenza Vaccines Marburg Gmbh Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy
EP3085373A1 (en) 2006-02-22 2016-10-26 3M Innovative Properties Company Immune response modifier conjugates
US8329721B2 (en) 2006-03-15 2012-12-11 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
US8063063B2 (en) * 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
EP2010537B1 (en) * 2006-03-23 2011-12-28 Novartis AG Imidazoquinoxaline compounds as immunomodulators
EP2010530A2 (en) * 2006-03-23 2009-01-07 Novartis AG Methods for the preparation of imidazole-containing compounds
CN101448523A (zh) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 无需冷藏储存流感疫苗
CA2647942A1 (en) 2006-03-31 2007-11-08 Novartis Ag Combined mucosal and parenteral immunization against hiv
US20100015168A1 (en) 2006-06-09 2010-01-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
WO2008008432A2 (en) * 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP2064230A2 (en) 2006-08-16 2009-06-03 Novartis AG Immunogens from uropathogenic escherichia coli
WO2008030511A2 (en) 2006-09-06 2008-03-13 Coley Pharmaceuticial Group, Inc. Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes
EP2066345B1 (en) 2006-09-11 2015-02-25 Novartis AG Making influenza virus vaccines without using eggs
EP2532362A1 (en) 2006-12-06 2012-12-12 Novartis AG Vaccines including antigen from four strains of influenza virus
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
EA201070066A1 (ru) 2007-06-27 2010-06-30 Новартис Аг Вакцины против гриппа с низким содержанием добавок
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
AU2008347400B2 (en) * 2008-01-15 2014-12-11 Meda Ab Treatment of colon diseases or prevention of colorectal carcinoma with imidazoquinoline derivatives
ES2546213T3 (es) * 2008-03-03 2015-09-21 Novartis Ag Compuestos y composiciones como moduladores de la actividad de TLR
US20110014230A1 (en) 2008-03-18 2011-01-20 Novartis Ag preparation of influenza virus vaccine antigens
ES2733084T3 (es) 2009-03-06 2019-11-27 Glaxosmithkline Biologicals Sa Antígenos de Chlamydia
EP2411521B1 (en) 2009-03-25 2015-01-14 The Board of Regents of The University of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
RU2508126C2 (ru) 2009-04-14 2014-02-27 Новартис Аг Композиции для иммунизации против staphylococcus aureus
JP2012525370A (ja) 2009-04-27 2012-10-22 ノバルティス アーゲー インフルエンザに対して防御するためのアジュバント添加ワクチン
AU2013203591B2 (en) * 2009-05-01 2017-01-19 University Court Of The University Of Dundee Treatment or prophylaxis of proliferative conditions
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
WO2011008974A2 (en) 2009-07-15 2011-01-20 Novartis Ag Rsv f protein compositions and methods for making same
ES2670799T3 (es) 2009-07-16 2018-06-01 Glaxosmithkline Biologicals Sa Inmunógenos desintoxicados de Escherichia coli
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
JP2013534248A (ja) * 2010-08-17 2013-09-02 スリーエム イノベイティブ プロパティズ カンパニー 脂質付加された免疫反応調節化合物の組成物、製剤及び方法
ES2575688T3 (es) 2010-12-16 2016-06-30 Sumitomo Dainippon Pharma Co., Ltd. Derivado de imidazo[4,5-c]quinolin-1-ilo útil en terapia
US10342862B2 (en) 2011-01-26 2019-07-09 Glaxosmithkline Biologicals, Sa RSV immunization regimen
PL3275892T3 (pl) 2011-05-13 2020-09-07 Glaxosmithkline Biologicals S.A. Przedfuzyjne antygeny RSV F
US8728486B2 (en) 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
EP2717919B1 (en) 2011-06-03 2016-08-03 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
EP3153180A1 (en) 2011-06-03 2017-04-12 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
US20130023736A1 (en) 2011-07-21 2013-01-24 Stanley Dale Harpstead Systems for drug delivery and monitoring
CN104080479B (zh) 2011-11-07 2019-11-05 葛兰素史密丝克莱恩生物有限公司 包括spr0096和spr2021抗原的运载体分子
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
CN112587658A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
SMT202000597T1 (it) 2013-01-07 2021-01-05 Univ Pennsylvania Composizioni e metodi per la cura del linfoma cutaneo cellule t
EP3632458B1 (en) 2013-07-26 2025-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of bacterial infections
AU2014347059B2 (en) 2013-11-05 2017-09-07 Solventum Intellectual Properties Company Sesame oil based injection formulations
EP2870974A1 (en) 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
US20170028079A1 (en) 2014-01-10 2017-02-02 Shanghai Birdie Biotech, Inc. Compounds and Compositions for Treating HER2 Positive Tumors
US10328140B2 (en) 2014-03-26 2019-06-25 Glaxosmithkline Biologicals S.A. Mutant staphylococcal antigens
JP6760919B2 (ja) 2014-07-09 2020-09-23 バーディー バイオファーマシューティカルズ インコーポレイテッド 腫瘍を治療するための抗pd−l1組み合わせ
CN112546231A (zh) * 2014-07-09 2021-03-26 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
CN105461767B (zh) * 2014-08-07 2019-03-12 富力 一种连翘苷的化学合成方法
CN112546238A (zh) 2014-09-01 2021-03-26 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
CN108137586B (zh) * 2015-09-14 2021-04-13 辉瑞大药厂 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物
JP2018531318A (ja) * 2015-09-29 2018-10-25 ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago ポリマーコンジュゲートワクチン
US10526309B2 (en) 2015-10-02 2020-01-07 The University Of North Carolina At Chapel Hill Pan-TAM inhibitors and Mer/Axl dual inhibitors
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技(北京)有限公司 用于治疗肿瘤的抗-cd20组合
CN115350279A (zh) 2016-01-07 2022-11-18 博笛生物科技有限公司 用于治疗肿瘤的抗-her2组合
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技(北京)有限公司 用于治疗肿瘤的抗-egfr组合
MX2019005502A (es) 2016-11-09 2020-10-01 Univ Texas Metodos y composiciones para inmunomodulacion adaptativa.
CN108794467A (zh) 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
US11517567B2 (en) 2017-06-23 2022-12-06 Birdie Biopharmaceuticals, Inc. Pharmaceutical compositions
CA3086439A1 (en) 2017-12-20 2019-06-27 3M Innovative Properties Company Amide substitued imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier
US11760773B2 (en) 2018-02-02 2023-09-19 Maverix Oncology, Inc. Small molecule drug conjugates of gemcitabine monophosphate
JP7251893B2 (ja) * 2018-02-28 2023-04-04 スリーエム イノベイティブ プロパティズ カンパニー N-1分枝基を有する置換イミダゾ[4,5-c]キノリン化合物
BR112020016859A2 (pt) 2018-02-28 2020-12-29 Pfizer Inc. Variantes de il-15 e usos da mesma
TWI816396B (zh) 2018-05-23 2023-09-21 美商輝瑞大藥廠 特異性針對gucy2c之抗體及其用途
DK3797121T3 (da) 2018-05-23 2024-07-08 Pfizer Antistoffer, der er specifikke for CD3, og anvendelser deraf
US11884662B2 (en) 2018-05-24 2024-01-30 3M Innovative Properties Company N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
US20210213010A1 (en) * 2018-07-24 2021-07-15 Torque Therapeutics, Inc. Tlr7/8 agonists and liposome compositions
ES2981659T3 (es) 2018-11-26 2024-10-09 Solventum Intellectual Properties Company Compuestos, composiciones y métodos de imidazo[4,5-c]quinolina sustituidos por alquil éter ramificado n-1
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
EP3921322B1 (en) * 2019-02-07 2025-09-03 Canwell Biotech Limited Phosphorus imidazoquinoline amine derivatives, pharmaceutical compositions and therapeutic methods thereof
WO2020168017A1 (en) 2019-02-12 2020-08-20 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
FI3947375T3 (fi) 2019-03-27 2024-05-30 Merck Patent Gmbh Imidatsolonyylikinoliiniyhdisteitä ja niiden terapeuttisia käyttötarkoituksia
JP7773011B2 (ja) * 2019-10-29 2025-11-19 ユウチャン チョウ, 4-アミノ-イミダゾキノリン化合物及びその使用
WO2021116420A1 (en) 2019-12-13 2021-06-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of tlr7 and/or tlr8 agonists for the treatment of leptospirosis
PE20230160A1 (es) 2019-12-17 2023-02-01 Pfizer Anticuerpos especificos para cd47, pd-l1 y sus usos
EP4182346A1 (en) 2020-07-17 2023-05-24 Pfizer Inc. Therapeutic antibodies and their uses
EP4199968A1 (en) 2020-08-20 2023-06-28 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
JP2023554377A (ja) * 2020-12-16 2023-12-27 スリーエム イノベイティブ プロパティズ カンパニー N-1分岐イミダゾキノリン、そのコンジュゲート、及び方法
WO2025104289A1 (en) 2023-11-17 2025-05-22 Medincell S.A. Antineoplastic combinations

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2135210A (en) * 1937-03-13 1938-11-01 John R Farrar Golf ball
US3314941A (en) 1964-06-23 1967-04-18 American Cyanamid Co Novel substituted pyridodiazepins
US3692907A (en) * 1970-10-27 1972-09-19 Richardson Merrell Inc Treating viral infections with bis-basic ethers and thioethers of fluorenone and fluorene and pharmaceutical compositons of the same
US3819190A (en) * 1972-10-02 1974-06-25 D Nepela Golf ball
US4284276A (en) * 1980-02-13 1981-08-18 Worst Joseph C Grooved golf ball
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
CA1271477A (en) * 1983-11-18 1990-07-10 John F. Gerster 1h-imidazo[4,5-c]quinolin-4-amines
ZA848968B (en) 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
JPH0327380Y2 (enExample) 1985-05-22 1991-06-13
US4880779A (en) * 1987-07-31 1989-11-14 Research Corporation Technologies, Inc. Method of prevention or treatment of AIDS by inhibition of human immunodeficiency virus
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5756747A (en) 1989-02-27 1998-05-26 Riker Laboratories, Inc. 1H-imidazo 4,5-c!quinolin-4-amines
DE69029212T2 (de) 1989-02-27 1997-05-22 Riker Laboratories Inc 4-Amino-1H-Imidazo(4,5-c)chinoline als antivirale Mittel
US5037986A (en) 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
NZ232740A (en) 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
US4988815A (en) * 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
US5054153A (en) * 1989-12-01 1991-10-08 Silliman Paul D Golf club cleaner
DK0553202T3 (da) * 1990-10-05 1995-07-03 Minnesota Mining & Mfg Fremgangsmåde til fremstilling af imidazo(4,5-c)quinolin-4-aminer
ES2186034T3 (es) * 1991-03-01 2003-05-01 Minnesota Mining & Mfg Intermedios para la preparacion de 1h-imidazo(4,5-c)quinolin-4-aminas 1-sustituidas, 2-sustituidas.
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5175296A (en) * 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
PH31245A (en) * 1991-10-30 1998-06-18 Janssen Pharmaceutica Nv 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives.
US5266575A (en) * 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
FR2692159B1 (fr) * 1992-06-10 1996-10-11 Vartan Berberian Boule pour jeux de boules et procedes d'obtention d'une telle boule.
US5395937A (en) * 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5648516A (en) 1994-07-20 1997-07-15 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
CZ288182B6 (en) 1993-07-15 2001-05-16 Minnesota Mining & Mfg Imidazo[4,5-c]pyridine-4-amines and pharmaceutical preparations based thereon
US5644063A (en) 1994-09-08 1997-07-01 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]pyridin-4-amine intermediates
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
JPH09116911A (ja) * 1995-10-20 1997-05-02 Canon Inc 撮像システム
JPH09208584A (ja) 1996-01-29 1997-08-12 Terumo Corp アミド誘導体、およびそれを含有する医薬製剤、および合成中間体
JPH09255926A (ja) 1996-03-26 1997-09-30 Diatex Co Ltd 粘着テープ
US5693811A (en) * 1996-06-21 1997-12-02 Minnesota Mining And Manufacturing Company Process for preparing tetrahdroimidazoquinolinamines
US5741908A (en) * 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
US5759109A (en) * 1996-09-09 1998-06-02 Martini; Byron Rocco Simulated golf ball instructional device
CA2268957C (en) 1996-10-25 2008-04-29 Minnesota Mining And Manufacturing Company Immune response modifier compounds for treatment of th2 mediated and related diseases
US5939090A (en) 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
WO1998030562A1 (en) * 1997-01-09 1998-07-16 Terumo Kabushiki Kaisha Novel amide derivatives and intermediates for the synthesis thereof
UA67760C2 (uk) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
JPH11222432A (ja) 1998-02-03 1999-08-17 Terumo Corp インターフェロンを誘起するアミド誘導体を含有する外用剤
JPH11255926A (ja) 1998-03-13 1999-09-21 Toray Ind Inc シリコーン成型品およびその製造方法
US6239965B1 (en) * 1998-05-22 2001-05-29 Matsushita Electric Industrial Co., Ltd. Electrolytic capacitor and method of producing the same
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
JP2000119271A (ja) * 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd 1h―イミダゾピリジン誘導体
EP1140091B1 (en) * 1999-01-08 2005-09-21 3M Innovative Properties Company Formulations comprising imiquimod or other immune response modifiers for treating cervical dysplasia
EP1495758A3 (en) 1999-01-08 2005-04-13 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US20020058674A1 (en) * 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
US6558951B1 (en) 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
JP2000247884A (ja) 1999-03-01 2000-09-12 Sumitomo Pharmaceut Co Ltd アラキドン酸誘発皮膚疾患治療剤
US6573273B1 (en) * 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6331539B1 (en) * 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6451810B1 (en) 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6376669B1 (en) 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
US6894060B2 (en) 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
US20020055517A1 (en) * 2000-09-15 2002-05-09 3M Innovative Properties Company Methods for delaying recurrence of herpes virus symptoms
JP2002145777A (ja) 2000-11-06 2002-05-22 Sumitomo Pharmaceut Co Ltd アラキドン酸誘発皮膚疾患治療剤
UA74593C2 (en) 2000-12-08 2006-01-16 3M Innovative Properties Co Substituted imidazopyridines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6660735B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6667312B2 (en) * 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
UA74852C2 (en) 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6545017B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6664265B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
WO2002046749A2 (en) 2000-12-08 2002-06-13 3M Innovative Properties Company Screening method for identifying compounds that selectively induce interferon alpha
US6525064B1 (en) * 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6545016B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6664264B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
CA2449754A1 (en) 2001-06-15 2002-12-27 3M Innovative Properties Company Immune response modifiers for the treatment of periodontal disease
MXPA04001972A (es) 2001-08-30 2005-02-17 3M Innovative Properties Co Metodos para hacer madurar celulas dendricas plasmacitoide utilizando moleculas modificadoras de respuesta enmune.
AU2002360278A1 (en) 2001-10-12 2003-11-11 Coley Pharmaceutical Gmbh Methods and products for enhancing immune responses using imidazoquinoline compounds
AU2002343728A1 (en) 2001-11-16 2003-06-10 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor pathways
US20030199538A1 (en) 2001-11-29 2003-10-23 3M Innovative Properties Company Pharmaceutical formulation comprising an immune response modifier
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
HUE025145T2 (en) 2002-02-22 2016-01-28 Meda Ab A method for reducing and treating immunosuppression induced by ultraviolet B radiation
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
JP2005531599A (ja) 2002-05-29 2005-10-20 スリーエム イノベイティブ プロパティズ カンパニー イミダゾ[4,5−c]ピリジン−4−アミンのための方法
EP1513524A4 (en) 2002-06-07 2008-09-03 3M Innovative Properties Co WITH ETHER SUBSTITUTED IMIDAZOPYRIDINE
DK1545597T3 (da) 2002-08-15 2011-01-31 3M Innovative Properties Co Immunstimulerende sammensætninger og fremgangsmåde til stimulering af en immunrespons
EP1542688A4 (en) 2002-09-26 2010-06-02 3M Innovative Properties Co 1H-imidazo dimers
AU2003287316A1 (en) 2002-12-11 2004-06-30 3M Innovative Properties Company Assays relating to toll-like receptor activity
AU2003287324A1 (en) 2002-12-11 2004-06-30 3M Innovative Properties Company Gene expression systems and recombinant cell lines
WO2004058759A1 (en) * 2002-12-20 2004-07-15 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
AU2003300184B8 (en) 2002-12-30 2009-12-03 3M Innovative Properties Company Immunostimulatory combinations
WO2004071459A2 (en) 2003-02-13 2004-08-26 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor 8
EP1599726A4 (en) 2003-02-27 2009-07-22 3M Innovative Properties Co SELECTIVE MODULATION OF TLR-MEDIATED BIOLOGICAL ACTIVITY
AU2004218349A1 (en) 2003-03-04 2004-09-16 3M Innovative Properties Company Prophylactic treatment of UV-induced epidermal neoplasia
TW200505458A (en) 2003-03-07 2005-02-16 3M Innovative Properties Co 1-amino 1h-imidazoquinolines
US8426457B2 (en) 2003-03-13 2013-04-23 Medicis Pharmaceutical Corporation Methods of improving skin quality
AU2004220465A1 (en) 2003-03-13 2004-09-23 3M Innovative Properties Company Method of tattoo removal
US7699057B2 (en) 2003-03-13 2010-04-20 3M Innovative Properties Company Methods for treating skin lesions
US20040192585A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
WO2004087049A2 (en) 2003-03-25 2004-10-14 3M Innovative Properties Company Selective activation of cellular activities mediated through a common toll-like receptor
JP2006522823A (ja) 2003-04-10 2006-10-05 スリーエム イノベイティブ プロパティズ カンパニー 免疫反応調節物質化合物の送達
BRPI0414045A (pt) 2003-09-05 2006-10-24 Anadys Pharmaceuticals Inc administração de ligantes de tlr7 e pró-medicamentos dos mesmos para tratamento de infecção por vìrus de hepatite c

Also Published As

Publication number Publication date
ZA200305275B (en) 2004-10-08
SK7152003A3 (en) 2003-09-11
TW584633B (en) 2004-04-21
HK1066005A1 (en) 2005-03-11
US6670372B2 (en) 2003-12-30
CN1253452C (zh) 2006-04-26
PL365995A1 (en) 2005-01-24
TWI222972B (en) 2004-11-01
BR0116047A (pt) 2003-09-30
SK287264B6 (sk) 2010-04-07
KR20030070050A (ko) 2003-08-27
CN1247575C (zh) 2006-03-29
PL392462A1 (pl) 2010-11-22
EP1341790B1 (en) 2007-02-14
AU3061802A (en) 2002-06-18
CN1479739A (zh) 2004-03-03
US20040092545A1 (en) 2004-05-13
SI1341790T1 (sl) 2007-06-30
RU2302418C2 (ru) 2007-07-10
JP2010031040A (ja) 2010-02-12
EE200300275A (et) 2003-10-15
RU2308456C2 (ru) 2007-10-20
EP1341791B1 (en) 2005-05-25
HK1069166A1 (en) 2005-05-13
JP2004532810A (ja) 2004-10-28
AR035664A1 (es) 2004-06-23
WO2002046191A3 (en) 2003-03-13
NO20032451D0 (no) 2003-05-28
ES2242782T3 (es) 2005-11-16
HUP0600600A2 (en) 2006-11-28
BR0116026A (pt) 2004-12-21
US6656938B2 (en) 2003-12-02
US20040106640A1 (en) 2004-06-03
EE200300268A (et) 2003-10-15
PL366330A1 (en) 2005-01-24
TWI293300B (en) 2008-02-11
NO326159B1 (no) 2008-10-13
DE60126645T2 (de) 2007-11-22
CN1252070C (zh) 2006-04-19
PL207340B1 (pl) 2010-12-31
EP1341789A2 (en) 2003-09-10
CZ20031562A3 (en) 2004-03-17
US6953804B2 (en) 2005-10-11
CA2436983A1 (en) 2002-06-13
AR035667A1 (es) 2004-06-23
AU3951602A (en) 2002-06-18
KR20040028691A (ko) 2004-04-03
RU2003116123A (ru) 2004-11-20
CA2436980C (en) 2011-03-29
WO2002046188A2 (en) 2002-06-13
KR20030070049A (ko) 2003-08-27
RU2003116649A (ru) 2005-02-10
WO2002046190A3 (en) 2003-07-17
WO2002046190A2 (en) 2002-06-13
DE60126645D1 (de) 2007-03-29
NZ526105A (en) 2004-11-26
CZ20031591A3 (cs) 2003-11-12
PT1341791E (pt) 2005-09-30
US20040077678A1 (en) 2004-04-22
EE200300270A (et) 2003-10-15
HRP20030466A2 (en) 2004-06-30
NO20032451L (no) 2003-07-16
US20050148619A1 (en) 2005-07-07
NZ526088A (en) 2004-12-24
PL365907A1 (en) 2005-01-10
MXPA03004975A (es) 2003-09-05
CN1537111A (zh) 2004-10-13
NZ526106A (en) 2004-11-26
AU3248202A (en) 2002-06-18
BR0116052A (pt) 2006-02-21
DE60117859D1 (de) 2006-05-04
CA2436846C (en) 2010-11-16
KR20040047733A (ko) 2004-06-05
AU3249702A (en) 2002-06-18
WO2002046188A3 (en) 2003-03-13
MXPA03005011A (es) 2003-09-05
ATE353895T1 (de) 2007-03-15
RU2315049C2 (ru) 2008-01-20
WO2002046193A2 (en) 2002-06-13
CA2436980A1 (en) 2002-06-13
JP2004523498A (ja) 2004-08-05
IL156043A0 (en) 2003-12-23
ZA200305270B (en) 2004-08-26
MXPA03005012A (es) 2003-09-05
CN1479738A (zh) 2004-03-03
AU2002239517B2 (en) 2006-11-02
WO2002046191A2 (en) 2002-06-13
HRP20030461A2 (en) 2004-06-30
MXPA03004973A (es) 2004-01-29
KR20040028690A (ko) 2004-04-03
RU2351598C2 (ru) 2009-04-10
NO20032449D0 (no) 2003-05-28
EE200300274A (et) 2003-10-15
NZ526087A (en) 2004-11-26
JP2004515501A (ja) 2004-05-27
SK7132003A3 (en) 2003-10-07
NZ526089A (en) 2004-11-26
SK6842003A3 (en) 2003-12-02
UA75622C2 (en) 2006-05-15
CA2430844A1 (en) 2002-06-13
NO20032595L (no) 2003-06-06
IL155904A0 (en) 2003-12-23
HRP20030464A2 (en) 2004-06-30
JP2004521092A (ja) 2004-07-15
DK1343784T3 (da) 2006-07-10
PT1341790E (pt) 2007-05-31
ZA200305271B (en) 2004-10-08
ATE319711T1 (de) 2006-03-15
WO2002046192A3 (en) 2003-02-13
BR0116470A (pt) 2005-08-16
AU2002239516B2 (en) 2006-11-09
DE60111076D1 (en) 2005-06-30
ZA200305272B (en) 2005-01-26
ZA200305273B (en) 2004-10-08
UA74852C2 (en) 2006-02-15
RU2003116059A (ru) 2005-02-10
PL366115A1 (en) 2005-01-24
DK1341790T3 (da) 2007-06-04
IL155950A0 (en) 2003-12-23
KR20040023576A (ko) 2004-03-18
IL156044A0 (en) 2003-12-23
HUP0600605A2 (en) 2006-11-28
AU3951702A (en) 2002-06-18
NO20032595D0 (no) 2003-06-06
NO20032473L (no) 2003-05-30
NO20032452D0 (no) 2003-05-28
RU2003116063A (ru) 2004-12-10
WO2002046192A2 (en) 2002-06-13
ATE296301T1 (de) 2005-06-15
AU2002232482B2 (en) 2006-10-19
IL155884A0 (en) 2003-12-23
ES2260323T3 (es) 2006-11-01
AR035669A1 (es) 2004-06-23
EP1341790A2 (en) 2003-09-10
SK287732B6 (en) 2011-07-06
EP1343784B1 (en) 2006-03-08
CY1105586T1 (el) 2010-07-28
NO20032452L (no) 2003-07-16
HRP20030467A2 (en) 2004-04-30
CZ295848B6 (cs) 2005-11-16
DK1341791T3 (da) 2005-09-19
HK1064383A1 (en) 2005-01-28
CA2436984A1 (en) 2002-06-13
US7612083B2 (en) 2009-11-03
AR035665A1 (es) 2004-06-23
EP1341792A2 (en) 2003-09-10
BR0116032A (pt) 2006-02-21
US20030212091A1 (en) 2003-11-13
JP4437189B2 (ja) 2010-03-24
SK7122003A3 (en) 2003-11-04
AR035666A1 (es) 2004-06-23
AU2002230618B2 (en) 2006-11-02
US6683088B2 (en) 2004-01-27
WO2002046189A2 (en) 2002-06-13
PL361948A1 (en) 2004-10-18
IL155903A0 (en) 2003-12-23
HUP0700062A2 (en) 2007-05-02
US7132429B2 (en) 2006-11-07
EE200300271A (et) 2003-10-15
AR035668A1 (es) 2004-06-23
CZ303462B6 (cs) 2012-09-26
NO20032449L (no) 2003-05-28
US20050234088A1 (en) 2005-10-20
EP1343784A2 (en) 2003-09-17
CZ20031561A3 (cs) 2004-04-14
HRP20030463A2 (en) 2004-04-30
NO20032596D0 (no) 2003-06-06
PL365883A1 (en) 2005-01-10
EP1341791A2 (en) 2003-09-10
NO20032473D0 (no) 2003-05-30
AU2002239530B2 (en) 2006-09-28
HUP0600338A2 (en) 2006-08-28
CZ20031592A3 (cs) 2004-01-14
MXPA03004972A (es) 2004-01-29
CA2436846A1 (en) 2002-06-13
CN1487939A (zh) 2004-04-07
SK7102003A3 (en) 2003-10-07
SK7112003A3 (en) 2003-12-02
CA2431151A1 (en) 2002-06-13
NZ526086A (en) 2005-11-25
JP2004515500A (ja) 2004-05-27
HUP0400704A2 (hu) 2004-06-28
NO20032596L (no) 2003-06-06
CY1106569T1 (el) 2012-01-25
ES2281456T3 (es) 2007-10-01
AU3953002A (en) 2002-06-18
HRP20030462A2 (en) 2004-04-30
JP2004529078A (ja) 2004-09-24
HRP20030467B1 (hr) 2009-04-30
BR0116464A (pt) 2006-02-21
WO2002046189A3 (en) 2003-03-20
DE60111076T2 (de) 2006-05-04
EE200300272A (et) 2003-10-15
WO2002046193A3 (en) 2003-02-27
CZ20031560A3 (en) 2004-05-12
AU2002232497B2 (en) 2006-11-02
CZ20031563A3 (cs) 2004-02-18
CN1511155A (zh) 2004-07-07
CN1894244A (zh) 2007-01-10
MXPA03004974A (es) 2003-09-05
US20020193396A1 (en) 2002-12-19
US20030158192A1 (en) 2003-08-21
ZA200305274B (en) 2004-10-18
EP1339715A2 (en) 2003-09-03
HUP0400710A2 (hu) 2004-06-28
CN1297554C (zh) 2007-01-31
US7049439B2 (en) 2006-05-23

Similar Documents

Publication Publication Date Title
DE60117859T2 (de) HARNSTOFFSUBSTITUIERTE IMIDAZOCHINOLINETHER und Arzneimittel, die diese umfassen.
DE60030293T2 (de) Harnstoffsubstituierte imidazochinoline
US6660735B2 (en) Urea substituted imidazoquinoline ethers
DE69835844T2 (de) Imidazonaphthyridine und ihre verwendung zur induzierung der biosynthese von cytokin
US6660747B2 (en) Amido ether substituted imidazoquinolines
US6664265B2 (en) Amido ether substituted imidazoquinolines
US20030139441A1 (en) Sulfonamido ether substituted imidazoquinolines
AU2002232497A1 (en) Urea substituted imidazoquinoline ethers
AU2002232482A1 (en) Amido ether substituted imidazoquinolines

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee